Nouscom
Switzerland · Biotech
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
Product
Nouscom develops immunotherapies designed to train the immune system to recognize cancer-associated neoantigens. The company is headquartered in Basel, Switzerland, with research and manufacturing activities in Italy.
Its viral-vector platform supports two clinical approaches: NOUS-209 delivers shared neoantigens in an off-the-shelf product, while NOUS-PEV is personalized to a patient’s tumor. NOUS-209 is being developed for people with Lynch syndrome and for mismatch repair-deficient or microsatellite instability-high colorectal cancer.
These programs remain investigational. The company is advancing NOUS-209 toward a global trial intended to support registration for cancer interception in Lynch syndrome carriers.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series D | €120M | M Ventures — LeadRevelation Partners — Lead5AM Ventures — ParticipantAndera Partners — ParticipantAngelini Investments — ParticipantAngelini Ventures — ParticipantBpifrance — ParticipantCDP Venture Capital — ParticipantEQT Life Sciences — ParticipantEuropean Investment Bank — ParticipantIndaco Ventures SGR — ParticipantNeva SGR — ParticipantPanakès Partners — ParticipantVersant Ventures — ParticipantXgen Ventures — Participant |